This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of -9.09% and 35.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 49.06% and 2.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 5.45% and 96.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of -2.83% and 6.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 17.46% and 9.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 20.54% and 126.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround
by Zacks Equity Research
Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lumos Pharma (LUMO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lumos Pharma's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Lumos Pharma.